{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceralasertib", "query": { "intervention": "Ceralasertib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceralasertib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T21:38:37.356Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06769126", "title": "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Lung Small Cell Carcinoma", "Lung Small Cell Carcinoma, A Subtype", "Lung Small Cell Carcinoma, I Subtype", "Lung Small Cell Carcinoma, N Subtype", "Lung Small Cell Carcinoma, P Subtype" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Monalizumab", "type": "BIOLOGICAL" }, { "name": "Platinum Compound", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Saruparib", "type": "DRUG" }, { "name": "Thoracic Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2025-11-06", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 148, "location_summary": "Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06769126" }, { "nct_id": "NCT03682289", "title": "Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Locally Advanced Pancreatic Cancer", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Renal Cell Carcinoma", "Metastatic Urothelial Carcinoma", "Metastatic Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage III Renal Cell Cancer", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Endometrial Cancer", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2019-01-17", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 3, "location_summary": "Duarte, California • San Francisco, California • Chicago, Illinois", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682289" }, { "nct_id": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 528, "start_date": "2017-12-18", "completion_date": "2026-09-11", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 17, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334617" }, { "nct_id": "NCT04699838", "title": "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Muhammad Furqan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-04-20", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 5, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04699838" }, { "nct_id": "NCT03579316", "title": "Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2018-12-07", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579316" }, { "nct_id": "NCT03878095", "title": "Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Refractory Cholangiocarcinoma", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-01-30", "completion_date": "2027-07-10", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 13, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Trumbull, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878095" }, { "nct_id": "NCT05061134", "title": "A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 194, "start_date": "2022-08-11", "completion_date": "2026-11-02", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 6, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Lutherville-Timonium", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061134" }, { "nct_id": "NCT04564027", "title": "A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 54, "start_date": "2020-12-01", "completion_date": "2025-02-18", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04564027" }, { "nct_id": "NCT03462342", "title": "Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Serous Carcinoma" ], "interventions": [ { "name": "Olaparib Pill", "type": "DRUG" }, { "name": "AZD6738", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 123, "start_date": "2018-03-09", "completion_date": "2025-07-21", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03462342" }, { "nct_id": "NCT02576444", "title": "OLAParib COmbinations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "AZD2281", "type": "DRUG" }, { "name": "AZD5363", "type": "DRUG" }, { "name": "AZD1775", "type": "DRUG" }, { "name": "AZD6738", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph Paul Eder", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2015-11", "completion_date": "2019-11-18", "has_results": true, "last_update_posted_date": "2022-12-28", "last_synced_at": "2026-09-04T21:38:37.356Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Cleveland, Ohio + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576444" } ] }